claim: enisamium is an inhibitor of the sars-cov-2 rna polymerase and shows improvement of recovery in covid-19 patients in an interim analysis of a clinical trial.
evidence_1: here, we report that enisamium, which can be administered orally, can prevent sars-cov-2 replication and that its metabolite vr17-04 can inhibit the sars-cov-2 rna polymerase in vitro .", "the researchers say the observations point to enisamium as a viable and accessible option for the treatment of sars-cov-2 infection and covid-19.", "( d ) quantification of sars-cov-2 rna genome levels in nhbe cells infected with sars-cov-2 after treatment with enisamium iodide.", "here, we report that enisamium, which can be administered orally, can prevent sars-cov-2 replication and that its metabolite vr17-04 can inhibit the sars-cov-2 rna polymerase in vitro.", 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  "the researchers say the findings suggest that enisamium is an inhibitor of sars-cov-2 rna synthesis and shortens recovery time among covid-19 patients who require oxygen supplementation.")